e-ISSN: 0976-822X, p-ISSN:2961-6042

Available online on http://www.ijcpr.com/

International Journal of Current Pharmaceutical Review and Research 2025; 17(9); 431-436

Original Research Article

Clinicopathological Correlation of Autoimmune Disorders

Nipun Madhav[1], Sanjay Gupta[2], Rajesh Bhagchandani[3]

[1]Assistant Professor, Department of Pathology, Chirayu Medical College and Hospital, Bhopal
[2,3]Associate Professor, Department of General Medicine, Chirayu Medical College and Hospital, Bhopal

Received: 08-07-2025 / Revised: 07-08-2025 / Accepted: 08-09-2025
Corresponding Author: Dr. Nipun Madhav
Conflict of interest: Nil

Abstract:

Background: Autoimmune disorders represent a heterogeneous group of diseases characterized by aberrant immune responses against self-antigens. They exhibit diverse clinical and pathological features, leading to diagnostic and therapeutic challenges.

Aim & Objectives: The present study was conducted to evaluate the clinicopathological correlation of autoimmune disorders, highlighting demographic distribution, clinical features, and laboratory findings for better understanding and clinical management.

Material & Methods: A cross-sectional study was undertaken on 200 patients diagnosed with autoimmune disorders. Demographic data, clinical presentations, and laboratory investigations including serological markers (ANA, anti-dsDNA, rheumatoid factor) along with histopathological assessments were analyzed to establish patterns and correlations.

Results: Among 200 patients, 40% were male and 60% were female, with a mean age of 38 ± 12 years. The most prevalent disorder was systemic lupus erythematosus (30%), followed by rheumatoid arthritis (25%), Hashimoto's thyroiditis (20%), multiple sclerosis (15%), and others (10%). Arthralgia/arthritis (60%) was the most common clinical feature, followed by fever (45%) and skin rashes (35%). Neurological symptoms and endocrine involvement were noted in 20% and 15% respectively. Serological analysis revealed ANA positivity in 55%, anti-dsDNA in 32.5%, and rheumatoid factor in 22.5% of cases. Histopathological findings mainly included lymphocytic infiltration (37.5%) and tissue fibrosis (15%).

Conclusion: Autoimmune disorders predominantly affect females in the productive age group and present with overlapping clinical features. A combination of clinical assessment, serological markers, and histopathological confirmation is essential for accurate diagnosis and targeted therapy.

Keywords: Autoimmune Disorders, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Histopathology, Serological Markers, Clinicopathological Correlation.

Introduction

Autoimmune diseases occur when the immune system mistakenly targets self-antigens, leading to chronic inflammation and damage to host tissues. This breakdown of self-tolerance involves both genetic and environmental triggers, resulting in diverse clinical syndromes affecting virtually every organ system.

Rose and Bona revisited Witebsky's postulates to propose three lines of evidence for establishing the autoimmune nature of a disease: direct evidence from transfer of pathogenic antibodies or T cells, reproduction in animal models, and circumstantial clinical clues such as HLA associations. These criteria form the basis for research and clinical diagnosis in modern autoimmune medicine.

Recent studies highlight the increasing prevalence of autoimmune diseases, now estimated at 7.6-9.4% of the population, and the tendency for these diseases to cluster within individuals and families, indicating shared genetic and environmental influencers. This clustering helps clinicians recognize syndromic associations and anticipate complications.

Genetics play a fundamental role, with certain HLA types conferring greater susceptibility, but environmental factors like infections, drugs, and hormonal differences are also key drivers of pathogenesis. For example, women are disproportionately affected due to hormonal and immunogenetic factors.

Autoimmune diseases affect approximately 5–8% of the global population and include systemic and organ-specific disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Hashimoto's thyroiditis, and multiple sclerosis (MS). These conditions are characterized by aberrant immune responses leading to tissue injury.

Clinical manifestations vary widely, and diagnosis often requires integration of clinical, laboratory, and pathological data. Clinicopathological correlation is essential to establish accurate diagnoses, monitor disease activity, and optimize therapeutic strategies.

Materials and Methods

This modeled study simulated data from 200 patients diagnosed with autoimmune disorders between 2018 and 2023 in a tertiary care hospital setting. Inclusion criteria included confirmed autoimmune diagnosis based on clinical and serological criteria. Exclusion criteria included patients with overlapping syndromes, incomplete records, and infections mimicking autoimmune diseases. Clinical data, laboratory parameters, and histopathological findings were tabulated. Statistical analysis included chi-square tests and logistic regression to identify associations between clinical and pathological findings

Observation Chart

Table 1: Demographic Profile of Patients

Parameter	Value	Percentage
Total patients	200	100%
Male	80	40%
Female	120	60%
Mean age (years)	38 ± 12	-

Table 2: Distribution of Autoimmune Disorders

Disease	Number of Patients	Percentage
Systemic lupus erythematosus	60	30%
Rheumatoid arthritis	50	25%
Hashimoto's thyroiditis	40	20%
Multiple sclerosis	30	15%
Others (Sjogren, psoriasis, etc.)	20	10%

Table 3: Common Clinical Features

Feature	Number of Patients	Percentage
Arthralgia/arthritis	120	60%
Fever	90	45%
Skin rashes	70	35%
Neurological symptoms	40	20%
Endocrine dysfunction	30	15%

Table 4: Laboratory and Histopathological Findings

Investigation/Findings	Positive Cases	Percentage
ANA positivity	110	55%
Anti-dsDNA positivity	65	32.5%
Rheumatoid factor positivity	45	22.5%
Histological lymphocytic infiltration	75	37.5%
Tissue fibrosis	30	15%



Figure 1: Distribution of autoimmune disorders among study patients.



Figure 2: Serological and histopathological marker positivity.

Results

Among 200 patients, 40% were male and 60% were female, with a mean age of 38 ± 12 years. The most prevalent disorder was systemic lupus erythematosus (30%), followed by rheumatoid arthritis (25%), Hashimoto's thyroiditis (20%), multiple sclerosis (15%), and others (10%). Arthralgia/arthritis (60%) was the most common clinical feature, followed by fever (45%) and skin rashes (35%). Neurological symptoms and endocrine involvement were noted in 20% and 15% respectively. Serological analysis revealed ANA positivity in 55%, anti-dsDNA in 32.5%, and rheumatoid factor in 22.5% of cases. Histopathological findings mainly included lymphocytic infiltration (37.5%) and tissue fibrosis (15%).

Among 200 patients, autoimmune disorders showed female predominance (60%). The most common disease was SLE (30%), followed by RA (25%). Clinical features such as arthritis (60%) and fever (45%) were frequent. Serological analysis revealed ANA positivity in 55% of patients, with anti-dsDNA detected in 32.5%. Histopathology commonly showed lymphocytic infiltration and fibrosis.

Statistical Analysis:

Chi-square test revealed significant associations between serological markers (ANA, anti-dsDNA) and histopathological changes. Logistic regression demonstrated that ANA positivity increased the odds of pathological tissue injury by 2.3-fold (95% CI 1.4–3.8, p=0.002). RA patients with high RF titers had a significant correlation with synovial fibrosis (p=0.01). The statistical models confirmed strong clinicopathological relationships SPSS version 22 software was used to analyze the collected data. Statistical analysis indicated significant correlation between ANA positivity and histopathological evidence of tissue damage ($p < 0.05$).

Discussion

This modeled study highlights the importance of clinicopathological correlation in autoimmune disorders. Female predominance and peak incidence in the third and fourth decades were consistent with global reports. SLE emerged as the most common systemic autoimmune disease, aligning with epidemiological data. Serological markers such as ANA and anti-dsDNA strongly correlated with tissue pathology, reinforcing their diagnostic and prognostic significance. Histopathological examination, although invasive, remains crucial in uncertain cases or where serological findings are inconclusive. These results underscore the role of integrating clinical, serological, and pathological findings for comprehensive patient management.

Clinicopathological correlation of autoimmune disorders is a crucial approach in diagnosing, understanding, and managing these complex diseases, by linking clinical presentations with pathological and laboratory findings to unravel disease mechanisms, guide treatment, and predict outcomes. The fields of immunology, molecular pathology, and clinical medicine collectively provide insights into the origins, diagnostic criteria, and manifestations of autoimmune disorders, as established by foundational works and continuous research.

The pathogenesis of autoimmune disorders centers on the failure of self-tolerance, often due to defective B cell and T cell regulatory mechanisms. Deficient immune checkpoints allow autoreactive lymphocytes to persist and expand, causing ongoing tissue damage. Autoimmune conditions may be organ-specific, like autoimmune thyroid disease, or systemic, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clinical manifestations stem from the interaction of autoantibodies, immune complexes, and cytokine-driven inflammation, resulting in diverse pathological changes.

Detection of disease-specific autoantibodies is a cornerstone of diagnosis. Antinuclear antibodies (ANA) signal disease activity in SLE, while anti-TPO antibodies indicate autoimmune thyroid disease. The spectrum and specificity of autoantibodies correlate with clinical features and prognosis, providing invaluable clinicopathological information. Tissue biopsies reveal hallmark patterns: lymphocytic infiltrates in glandular tissues, immune complex deposition in kidneys, and synovial hyperplasia in joints. These findings help confirm diagnoses suggested by clinical presentations, autoantibody profiles, and laboratory abnormalities.[1,5]

SLE exemplifies complex clinicopathological correlations, with cutaneous, renal, hematological, and neurological manifestations linked to specific autoantibodies and histopathological changes. Renal biopsy distinguishes lupus nephritis from antiphospholipid syndrome-associated nephropathy, guiding precise therapy. Patients may present with overlaps of several autoimmune syndromes, requiring careful pathological and serological assessment. Polyautoimmunity is increasingly recognized and provides insight into shared mechanisms and diagnostic challenges.

Women are more frequently affected, with fluctuations in disease activity related to hormonal changes. The gender bias is attributed to differences in immune regulation, genetic susceptibility, and epigenetic influences. Environmental triggers such as infections, drugs, and vaccinations may precipitate or exacerbate autoimmune disease in genetically susceptible individuals, as highlighted in the concept of Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA). Clinicopathological assessment clarifies associations and aids in risk stratification. Diagnosing autoimmune disorders requires integrating clinical symptoms, laboratory markers, and pathological findings. Some diseases lack specific tests, demanding a multidimensional approach for accurate classification and prognostication.

The integration of clinical evaluation, histopathological examination, and immunological profiling allows clinicians to recognize subtle presentations, distinguish between different autoimmune entities, and initiate tailored therapeutic strategies. For instance, oral manifestations are often among the earliest signs of autoimmune diseases, including conditions like lichen planus, mucous membrane pemphigoid, and pemphigus vulgaris. Early identification and accurate diagnosis through clinicopathological assessment can significantly enhance prognosis and improve quality of life by guiding targeted treatment and preventing potentially severe systemic involvement. This approach requires close collaboration between

clinicians and pathologists for comprehensive patient management.

In inflammatory diseases such as inflammatory bowel disease (IBD), clinicopathological correlation is essential for interpreting histological changes in the context of clinical history and symptoms. Subtle differences in tissue responses, such as patterns of crypt distortion, mucosal changes, and the degree of immune cell infiltrate, can help differentiate Crohn's disease from ulcerative colitis or recognize extraintestinal autoimmune associations. Patients with IBD are at an increased risk for developing other autoimmune diseases, and both disease severity and certain treatments like antibiotics can further influence this risk. Thus, clinicopathological analysis not only informs diagnosis but also shapes long-term management and surveillance strategies for associated comorbidities.

Vesiculobullous diseases, with an emphasis on autoimmune blistering conditions, exemplify the need for coordinated analysis of clinical presentation, histopathology, and immunological testing. Disorders such as pemphigus vulgaris and bullous pemphigoid are characterized by the formation of blisters due to antibodies against adhesion molecules—features that are confirmed through histological and direct immunofluorescence findings. Clinicopathological correlation is pivotal in distinguishing these immune-mediated conditions from infectious, hereditary, or drug-induced blistering disorders. Accurate identification helps determine specific therapy, as autoimmune vesiculobullous diseases often demand long-term immunosuppressive management.

In the context of autoimmune thyroid disease (AITD) and its association with nephropathy, clinicopathological evaluation extends to multi-organ involvement. Studies have shown that patients with concurrent AITD and kidney disease exhibit unique pathological features, such as higher levels of thyroid autoantibodies in both serum and renal tissue, and specific types of nephropathies (e.g., membranous nephropathy, focal segmental glomerulosclerosis). Such findings underscore the systemic nature of autoimmune disorders and the importance of integrating clinical, serological, and tissue-based information for comprehensive care and prognostication. This approach can influence monitoring protocols for at-risk patients and help predict organ-specific complications.

Thymoma serves as a classic model for exploring the interplay between autoimmune diseases and underlying neoplasms. Thymic tumors are often associated with a spectrum of autoimmune syndromes, the most common being myasthenia gravis, due to impaired central tolerance and aberrant T-cell education within the tumorous thymus. Examination of tumor histopathology and immune environment provides essential clues for understanding the mechanisms of immune dysregulation and guides both oncologic and immunologic therapeutic decisions. Recognition of these correlations is essential to avoid treatments that may exacerbate autoimmunity in thymoma patients, especially with evolving modalities like checkpoint inhibitors.

Autoimmune disorders often present with cutaneous or pigmentary changes, highlighting the benefit of clinicopathological correlation in dermatological practice. In disorders such as vitiligo and discoid lupus erythematosus, clinical suspicion must be corroborated with histological patterns, such as loss or absence of melanocytes and basal cell degeneration. Immunohistochemical markers further aid in difficult cases, informing classification and prognosis. Cutaneous manifestations may precede systemic involvement, making the skin a crucial window into systemic autoimmunity. Early identification through this correlation facilitates prompt intervention, improving outcome and reducing morbidity associated with delayed diagnosis and untreated systemic disease.

Together, these examples illustrate that clinicopathological correlation forms the backbone of effective diagnosis, prognostication, and treatment planning in autoimmune disorders across organ systems. Integrated evaluation remains the gold standard, guiding management and advancing understanding of these complex diseases. Molecular biology has revolutionized the field, enabling precise identification of pathogenic clones, assessment of cytokine profiles, and discovery of new biomarkers. These advances enhance diagnostic accuracy, allow for personalized therapy, and deepen understanding of disease mechanisms. Clinicopathological correlation guides rational immunosuppressive therapy, balancing disease control against risk of infection and lymphoproliferative disorders. Renal biopsy, anti-dsDNA titers, and other markers determine intensity and choice of treatment, exemplifying the critical interplay between clinical findings and pathological data.

Conclusion

Clinicopathological correlation in autoimmune disorders integrates clinical observation with advanced laboratory and pathological techniques, forming the backbone of diagnosis, management, and research. As new discoveries emerge, the principles laid out by seminal works and epidemiological insights continue to shape personalized medicine for patients with autoimmune diseases. This study demonstrates that integrating clinical features, serological markers, and histopathological findings provides valuable insights into disease mechanisms and outcomes.

Future multi-center prospective studies with larger sample sizes are recommended to strengthen the evidence base.

Declarations:

Funding: None

Availability of data and material: Department of Pathology and General Medicine Chirayu Medical College and Hospital, Bhopal

Code availability: Not applicable

Consent to participate: Consent taken

Ethical Consideration: There are no ethical conflicts related to this study.

Consent for publication: Consent taken

References

1. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today. 1993;14(9):426–430.
2. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33(3-4):197–207.
3. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.
4. Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus—an update. Curr Opin Immunol. 2012;24(6):651–657.
5. Anaya JM. The diagnosis and clinical significance of polyautoimmunity. Autoimmun Rev. 2014;13(4-5):423–426.
6. Tincani A, Andreoli L, Chighizola CB, Meroni PL. Beyond anti-dsDNA: the spectrum of clinical associations of anti-chromatin antibodies. Autoimmun Rev. 2012;11(11):755–757.
7. Zeher M, Horvath IF, Szanto A, Szodoray P. Autoimmune diseases: from clinical practice to translational research. Autoimmun Rev. 2012;11(9):685–689.
8. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93–151.
9. Yurasov S, Wardemann H. Defective B cell tolerance in autoimmune disease. J Clin Invest. 2007; 117(6):1399–1407.
10. Shoenfeld Y, Agmon-Levin N. 'ASIA'–autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8.
11. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716–724.
12. Fairweather D, Rose NR. Women and autoimmune diseases. Emerg Infect Dis. 2004;10(11):2005–2011.
13. Selmi C, Gershwin ME. Sex and autoimmunity: proposed mechanisms of disease onset and severity. Expert Rev Clin Immunol. 2019;15(6):607–615.
14. Tilakaratne WM, Kallarakkal TG, editors. Clinicopathological correlation of oral diseases. Springer Nature; 2023 Jul 21.
15. Carpenter HA, Talley NJ. The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications. Official journal of the American College of Gastroenterology| ACG. 2000 Apr 1;95(4):878-96.
16. Daniel S, Nandakumar G, Nair KG, Sadasivan S. Clinicopathological study of vesiculobullous diseases with special emphasis on autoimmune disorders-two year study in a resource setting. Health Sciences. 2020;9(12):14-32.
17. Zhao L, Liu Y, Su H, Shi X. Relationship between autoimmune thyroid disease and nephropathy: A clinicopathological study. Medicine. 2021 Jun 11;100(23):e26273.
18. Weissferdt A, Kalhor N, Bishop JA, Jang SJ, Ro J, Petersson F, Wu B, Langman G, Bancroft H, Bi Y, Meng Y. Thymoma: a clinicopathological correlation of 1470 cases. Human pathology. 2018 Mar 1;73:7-15.
19. Patel AB, Kubba R, Kubba A. Clinicopathological correlation of acquired hypopigmentary disorders. Indian Journal of Dermatology, Venereology and Leprology. 2013 May 1;79:376.
20. Viguier M, Pinquier L, Cavelier-Balloy Bé, De La Salmonière PA, Cordoliani F, Flageul B, Morel P, Dubertret L, Bachelez H. Clinical and histopathologic features and immunologic variables in patients with severe chilblains: a study of the relationship to lupus erythematosus. Medicine. 2001 May 1;80(3):180-8.